United Therapeutics (NASDAQ:UTHR) Price Target Raised to $643.00

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by investment analysts at Royal Bank Of Canada from $587.00 to $643.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 28.87% from the company’s current price.

Other research analysts have also issued reports about the company. UBS Group reissued a “buy” rating on shares of United Therapeutics in a report on Tuesday, February 17th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright upped their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $519.40.

United Therapeutics Price Performance

UTHR stock traded down $36.13 during trading hours on Thursday, reaching $498.97. The stock had a trading volume of 211,258 shares, compared to its average volume of 343,083. The stock has a 50-day simple moving average of $484.71 and a 200 day simple moving average of $444.09. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $537.19. The stock has a market capitalization of $21.49 billion, a PE ratio of 18.89, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the prior year, the firm earned $6.19 EPS. United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. On average, sell-side analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $478.58, for a total value of $10,768,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 21,000 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the transaction, the chief financial officer owned 8,142 shares in the company, valued at approximately $3,908,078.58. The trade was a 72.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 411,954 shares of company stock worth $199,552,088. 10.30% of the stock is owned by insiders.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics during the fourth quarter worth about $31,000. Institutional investors own 94.08% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and record FY revenue support upside — UTHR reported $7.70 EPS (vs. $6.78 est.) and record 2025 revenue of $3.18B, which underpinned investor confidence in profitability and margin strength. BusinessWire press release
• Positive Sentiment: Management set a near‑term growth target (≈$4B run rate by 2027) tied to several late‑stage/new product launches — gives a clear growth thesis that likely drove optimistic re‑rating and buy interest. Seeking Alpha
• Positive Sentiment: Bullish options activity and short‑term trader positioning amplified upside after the print — unusually large call buying signaled traders expecting further upside or volatility. Zacks
• Neutral Sentiment: Analysts remain mixed — several firms maintained Holds (BTIG, Morgan Stanley) and Wells Fargo raised its target to $466 but kept an Equal‑Weight stance, signaling cautious near‑term views despite pipeline upside. Benzinga (Wells Fargo note)
• Negative Sentiment: Revenue missed the quarter (~$790.2M vs. ~$814.8M expected), which triggered profit‑taking and reminded investors top‑line execution matters for valuation. Investing.com
• Negative Sentiment: Material insider selling — the COO disclosed a multi‑lot sale (14,440 shares) and a director sold 1,000 shares in late Feb; heavy insider dispositions can weigh on investor sentiment and add selling pressure. InsiderTrades / SEC filings

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.